{"DataElement":{"publicId":"5143999","version":"1","preferredName":"Patient Treated Metastatic Malignant Neoplasm in the Brain Diagnosis Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"The coded response indicating that a patient with previously treated known brain metastases meets additional criteria for participation in a clinical trial.","longName":"TRT_BRAIN_MET_CD_IND","context":"Theradex","contextVersion":"1","DataElementConcept":{"publicId":"5143998","version":"1","preferredName":"Patient Treated Metastatic Malignant Neoplasm in the Brain Diagnosis Clinical Trial Eligibility Criteria","preferredDefinition":"A person who receives medical attention, care, or treatment, or who is registered with medical professional or institution with the purpose to receive medical care when necessary._Providing treatment for._A malignant neoplasm that has spread to the brain from another anatomic site or system. The majority are carcinomas (usually lung or breast carcinomas)._The investigation, analysis and recognition of the presence and nature of disease, condition, or injury from expressed signs and symptoms; also, the scientific determination of any kind; the concise results of such an investigation._Characteristics which are necessary to allow a subject to participate in a clinical study, as outlined in the study protocol. The concept covers inclusion and exclusion criteria.","longName":"2177068v1.0:5143996v1.0","context":"Theradex","contextVersion":"1","ObjectClass":{"publicId":"2177068","version":"1","preferredName":"Patient","preferredDefinition":"A person who requires medical care.","longName":"Patient","context":"CTEP","contextVersion":"2.31","Concepts":[{"longName":"Patient","conceptCode":"C16960","definition":"A person who receives medical attention, care, or treatment, or who is registered with medical professional or institution with the purpose to receive medical care when necessary.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"ACAAECCE-7AB6-657B-E034-0003BA0B1A09","latestVersionIndicator":"Yes","beginDate":"2002-10-29","endDate":null,"createdBy":"SBREXT","dateCreated":"2002-10-29","modifiedBy":"SBR","dateModified":"2005-03-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"5143996","version":"1","preferredName":"Treating Metastatic Malignant Neoplasm in the Brain Diagnosis Clinical Trial Eligibility Criteria","preferredDefinition":"Providing treatment for.:A malignant neoplasm that has spread to the brain from another anatomic site or system. The majority are carcinomas (usually lung or breast carcinomas).:The investigation, analysis and recognition of the presence and nature of disease, condition, or injury from expressed signs and symptoms; also, the scientific determination of any kind; the concise results of such an investigation.:Characteristics which are necessary to allow a subject to participate in a clinical study, as outlined in the study protocol. The concept covers inclusion and exclusion criteria.","longName":"C25705:C3813:C15220:C16112","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Treating","conceptCode":"C25705","definition":"Providing treatment for.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"3"},{"longName":"Metastatic Malignant Neoplasm in the Brain","conceptCode":"C3813","definition":"A malignant neoplasm that has spread to the brain from another anatomic site or system. The majority are carcinomas (usually lung or breast carcinomas).","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Diagnosis","conceptCode":"C15220","definition":"The investigation, analysis and recognition of the presence and nature of disease, condition, or injury from expressed signs and symptoms; also, the scientific determination of any kind; the concise results of such an investigation.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Clinical Trial Eligibility Criteria","conceptCode":"C16112","definition":"Characteristics which are necessary to allow a subject to participate in a clinical study, as outlined in the study protocol. The concept covers inclusion and exclusion criteria.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2CF20F00-C9A3-BD67-E050-BB89AD432467","latestVersionIndicator":"Yes","beginDate":"2016-02-29","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2016-02-29","modifiedBy":"ONEDATA","dateModified":"2016-02-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008525","version":"1","preferredName":"Eligibility","preferredDefinition":"trial-specific criteria that a patient must meet to be enrolled.","longName":"ELIG","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B1EC3968-9F25-305A-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-16","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-16","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"2CF20F00-C9B4-BD67-E050-BB89AD432467","latestVersionIndicator":"Yes","beginDate":"2016-02-29","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2016-02-29","modifiedBy":"SBR","dateModified":"2016-06-06","changeDescription":"9881_Theradex_02.29.16_ghd","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"3298541","version":"1","preferredName":"Yes No Not Applicable Code Indicator","preferredDefinition":"Indicator to represent a response of Yes, No, or Not Applicable._The affirmative response to a question or activity._The non-affirmative response to a question._Determination that a value is not relevant in the current context._A system of numbered categories for representation of data.","longName":"YES_NO_NA_CD_IND","context":"CCR","contextVersion":"1","type":"Enumerated","dataType":"CHARACTER","minLength":"1","maxLength":"1","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"X","valueDescription":"Not applicable","ValueMeaning":{"publicId":"2581003","version":"1","preferredName":"Not applicable","longName":"2581003v1.00","preferredDefinition":"Determination of a value is not relevant in the current context.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Not Applicable","conceptCode":"C48660","definition":"Determination of a value is not relevant in the current context.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE88-0978-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2003-12-31","endDate":null,"createdBy":"SBREXT","dateCreated":"2003-12-31","modifiedBy":"CLOHNES","dateModified":"2023-11-09","changeDescription":null,"administrativeNotes":"2023.3.6 Added Alt VM-COG. ak","unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B04AC04D-C223-0627-E040-BB89AD432C31","beginDate":"2002-02-11","endDate":null,"createdBy":"REEVESD","dateCreated":"2011-10-27","modifiedBy":"ONEDATA","dateModified":"2011-10-27","deletedIndicator":"No"},{"value":"N","valueDescription":"No","ValueMeaning":{"publicId":"2559515","version":"1","preferredName":"No","longName":"2559515","preferredDefinition":"The non-affirmative response to a question.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"No","conceptCode":"C49487","definition":"The non-affirmative response to a question.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-B588-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2002-02-13","endDate":null,"createdBy":"SBR","dateCreated":"2002-02-13","modifiedBy":"GDEEN","dateModified":"2024-01-02","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B04AC04D-C22D-0627-E040-BB89AD432C31","beginDate":"2002-08-22","endDate":null,"createdBy":"REEVESD","dateCreated":"2011-10-27","modifiedBy":"ONEDATA","dateModified":"2011-10-27","deletedIndicator":"No"},{"value":"Y","valueDescription":"Yes","ValueMeaning":{"publicId":"2560453","version":"1","preferredName":"Yes","longName":"2560453","preferredDefinition":"The affirmative response to a question or activity.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Yes","conceptCode":"C49488","definition":"The affirmative response to a question.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-B932-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2002-02-13","endDate":null,"createdBy":"SBR","dateCreated":"2002-02-13","modifiedBy":"CLOHNES","dateModified":"2023-09-26","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B04AC04D-C237-0627-E040-BB89AD432C31","beginDate":"2002-08-22","endDate":null,"createdBy":"REEVESD","dateCreated":"2011-10-27","modifiedBy":"ONEDATA","dateModified":"2011-10-27","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"2008551","version":"1","preferredName":"Assessments","preferredDefinition":"evaluations of the patient and the patient's disease.","longName":"ASSESS","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B22DA727-6718-5A2D-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-19","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-19","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"3298540","version":"1","preferredName":"Yes No Not Applicable Code Indicator","preferredDefinition":"The affirmative response to a question or activity.:The non-affirmative response to a question.:Determination that a value is not relevant in the current context.:A system of numbered categories for representation of data.:An event, entity or condition that typically characterizes a prescribed environment or situation and determines or aids in determining whether certain stated circumstances exist or criteria are satisfied.","longName":"3298540v1.0","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Yes","conceptCode":"C49488","definition":"The affirmative response to a question.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"4"},{"longName":"No","conceptCode":"C49487","definition":"The non-affirmative response to a question.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"3"},{"longName":"Not Applicable","conceptCode":"C48660","definition":"Determination of a value is not relevant in the current context.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Code","conceptCode":"C25162","definition":"A symbol or combination of symbols which is assigned to the members of a collection.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Indicator","conceptCode":"C25180","definition":"An event, entity or condition that typically characterizes a prescribed environment or situation and determines or aids in determining whether certain stated circumstances exist or criteria are satisfied.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B04AC04D-C1F2-0627-E040-BB89AD432C31","latestVersionIndicator":"Yes","beginDate":"2011-10-27","endDate":null,"createdBy":"REEVESD","dateCreated":"2011-10-27","modifiedBy":"ONEDATA","dateModified":"2011-10-27","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"CTMS:Clinical Trials Monitoring Service","workflowStatus":"RELEASED","registrationStatus":"Application","id":"B04AC04D-C203-0627-E040-BB89AD432C31","latestVersionIndicator":"Yes","beginDate":"2011-10-27","endDate":null,"createdBy":"REEVESD","dateCreated":"2011-10-27","modifiedBy":"MAESKEB","dateModified":"2016-01-20","changeDescription":"Created to support Theradex design of CRFs for NCI CCR trials","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[{"publicId":"3876352","version":"1","longName":"Inclusion Criteria","context":"Theradex","ClassificationSchemeItems":[{"publicId":"3876426","version":"1","longName":"Physical & Concomitant Requirements","context":"Theradex"}]}],"AlternateNames":[{"name":"NRG","type":"USED_BY","context":"NRG"}],"ReferenceDocuments":[{"name":"If patient has known and trea","type":"Preferred Question Text","description":"If patient has known and treated brain metastases, are all of the following criteria met:  lesions have remained radiologically stable for at least six weeks after completion of brain irradiation or stereotactic brain radiosurgery, and remain stable at the time of study entry and there is no mass effect present radiologically and no steroids requirement for symptom control for more than 4 weeks?","url":null,"context":"Theradex"},{"name":"Theradex - 1","type":"Alternate Question Text","description":"If patient has brain metastases, does the patient meet the following criteria: No leptomeningeal disease is present; Intracranial disease is controlled by prior local therapies (craniotomy, stereotactic radiosurgery, whole brain irradiation), as evidenced by brain MRI 4 weeks post treatment indicating no new intracranial disease; and stable or decreasing dose of steroids provided patient on less than 20mg of prednisone or its equivalent daily?","url":null,"context":"Theradex"},{"name":"Theradex - 2","type":"Alternate Question Text","description":"If patient has known and treated brain metastases, have the lesions have improved or remained stable radiographically and clinically for at least 6 weeks after completion of brain irradiation or stereotactic brain radiosurgery and patient has been off steroids for at least 6 weeks?","url":null,"context":"Theradex"},{"name":"Theradex - 3","type":"Alternate Question Text","description":"If patient has brain metastases, does the patient meet the following criteria: No leptomeningeal disease is present; Intracranial disease is controlled by prior local therapies (craniotomy, stereotactic radiosurgery, whole brain irradiation), as evidenced by brain MRI 4 weeks post treatment indicating no new intracranial disease; and Stable or decreasing dose of steroids provided patient on less than or equal to 20mg of prednisone or its equivalent daily?","url":null,"context":"Theradex"},{"name":"Theradex - 4","type":"Alternate Question Text","description":"If patient has brain metastases or spinal cord compression previously that were treated by radiation and/or surgery, was local treatment was greater than 30 days ago, most recent MRI demonstrates stability or decrease in size of all lesions, and the patient has no current neurologic symptoms related to the metastases and treatment and no requirement for corticosteroids related to the prior treatment?","url":null,"context":"Theradex"},{"name":"Theradex - 5","type":"Alternate Question Text","description":"If patient has brain metastases that has been treated, does patient show radiographic stability?","url":null,"context":"Theradex"},{"name":"Theradex - 6","type":"Alternate Question Text","description":"If patient has previously treated brain metastases, are they stable (without evidence of progression by imaging for at least 4 weeks prior to the first dose of trial treatment and any neurologic symptoms have returned to baseline), have no evidence of new or enlarging brain metastases, and are not requiring steroids for at least 7 days prior to trial treatment?","url":null,"context":"Theradex"},{"name":"Theradex - 7","type":"Alternate Question Text","description":"If patient has previously treated brain metastases, are they stable (without evidence of progression by imaging using the same modality for each assessment, either MIR or CT, for at least 4 weeks prior to the first dose of trial treatment and any neurologic symptoms have returned to baseline), have no evidence of new or enlarging brain metastases and are not requiring steroids for at least 7 days prior to trial treatment?","url":null,"context":"Theradex"},{"name":"Theradex - 9","type":"Alternate Question Text","description":"If the patient has brain metastases that have been previously treated, the metastases were not accompanied by seizures and baseline brain MRI scan prior to study entry demonstrates no current evidence of brain metastases and all patients with CNS metastases must be stable for more than 3 months after treatment and off steroid treatment prior to study enrollment?","url":null,"context":"Theradex"},{"name":"Theradex - 8","type":"Alternate Question Text","description":"If patient has known and treated brain metastases, have the lesions improved or remained stable radiographically and clinically for at least 6 weeks after completion of brain irradiation or stereotactic brain radiosurgery and patient has been off steroids for at least 6 weeks?","url":null,"context":"Theradex"},{"name":"Theradex - 10","type":"Alternate Question Text","description":"Has patient been off any systemic corticosteroids for the treatment of brain metastases for at least 14 days prior to enrollment?","url":null,"context":"Theradex"},{"name":"Theradex - 11","type":"Alternate Question Text","description":"If the patient has brain metastases that have been previously treated, the metastases were not accompanied by seizures and baseline brain MRI scan prior to study entry demonstrates no current evidence of brain metastases?","url":null,"context":"Theradex"},{"name":"Theradex - 12","type":"Alternate Question Text","description":"If patient has treated brain metastases, there is no evidence of progression for at least 4 weeks after CNS-directed treatment, as ascertained by clinical examination and brain imaging (MRI or computed tomography [CT] scan) during the screening period?","url":null,"context":"Theradex"},{"name":"Theradex - 13","type":"Alternate Question Text","description":"If patient has treated brain metastases, there is no evidence of progression for at least 4 weeks after central nervous system (CNS)-directed treatment as ascertained by clinical examination and brain imaging (MRI or CT scan) during the screening period, the patient is on stable steroid doses and is taking an anti-seizure medication that does not cause drug-drug interaction?","url":null,"context":"Theradex"},{"name":"Theradex - 15","type":"Alternate Question Text","description":"If patient has previously treated brain metastases, are they stable (without evidence of progression by imaging using the same modality for each assessment, either MRI or CT, for at least 4 weeks prior to the first dose of trial treatment and any neurologic symptoms have returned to baseline), have no evidence of new or enlarging brain metastases and are not requiring steroids for at least 7 days prior to trial treatment?","url":null,"context":"Theradex"},{"name":"Theradex - 14","type":"Alternate Question Text","description":"If patient has previously treated brain metastases, are they stable (without evidence of progression by imaging for at least four weeks prior to the first dose of trial treatment and any neurologic symptoms have returned to baseline), have no evidence of new or enlarging brain metastases, and are not using steroids for at least 7 days prior to trial treatment?","url":null,"context":"Theradex"},{"name":"Theradex - 17","type":"Alternate Question Text","description":"If patient has CNS metastases, have they been adequately treated and have neurological symptoms returned to baseline?","url":null,"context":"Theradex"},{"name":"Theradex - 16","type":"Alternate Question Text","description":"If patient has CNS metastases, have they been adequately treated and neurological symptoms returned to baseline or are controlled for at least 2 weeks prior to study enrollment?","url":null,"context":"Theradex"},{"name":"Theradex - 18","type":"Alternate Question Text","description":"If patient has treated brain metastases, follow-up brain imaging after central nervous system (CNS)-directed therapy shows no evidence of progression and are off steroid support for at least 4 weeks after treatment for metastases is complete and within 28 days prior to the first dose of study treatment?","url":null,"context":"Theradex"},{"name":"NRG_CRF_Text_1","type":"Alternate Question Text","description":"Has the patient had brain metastases previously treated with radiotherapy?","url":null,"context":"NRG"},{"name":"Theradex - 19","type":"Alternate Question Text","description":"If patient has treated brain metastases, does the follow-up brain imaging after central nervous system (CNS)-directed therapy show no evidence of progression, are clinically asymptomatic and have not received systemic corticosteroids for at least 28 days?","url":null,"context":"Theradex"},{"name":"Theradex - 20","type":"Alternate Question Text","description":"If patient has treated brain metastases, does patient have stable symptoms and no ongoing requirement for corticosteroids as therapy for brain metastases?","url":null,"context":"Theradex"},{"name":"Theradex - 21","type":"Alternate Question Text","description":"If patient has treated brain metastases, is patient stable for at least 4 weeks post radiation therapy and off corticosteroids, as ascertained by clinical examination and brain imaging (magnetic resonance imaging [MRI] or computed tomography [CT] scan) during the screening period?","url":null,"context":"Theradex"},{"name":"Theradex - 22","type":"Alternate Question Text","description":"If patient has treated brain metastases that are no longer symptomatic and require no treatment with corticosteroids or anticonvulsants, have they recovered from the acute toxic effect of radiotherapy and a minimum of 2 weeks has elapsed between the end of the whole-brain radiation therapy and study treatment?","url":null,"context":"Theradex"},{"name":"Theradex - 24","type":"Alternate Question Text","description":"If patient has treated brain metastases, does follow-up brain imaging after central nervous system (CNS)-directed therapy show no evidence of progression (CNS   metastases have been clinically stable for at least 4 weeks prior to screening and baseline scans show no evidence of new or enlarged metastasis)?","url":null,"context":"Theradex"},{"name":"Theradex - 23","type":"Alternate Question Text","description":"If patient has previously treated brain metastases, are they radiologically stable, i.e., without evidence of progression for at least 4 weeks by repeat imaging (note that the repeat imaging should be performed during study screening) and clinically stable and without requirement of steroid treatment for at least 14 days prior to the first dose of study intervention?","url":null,"context":"Theradex"},{"name":"Theradex - 26","type":"Alternate Question Text","description":"If patient has treated brain metastases, has brain metastatic disease remained stable for greater than or equal to 1 month without requiring steroid and anti-seizure medication?","url":null,"context":"Theradex"},{"name":"Theradex - 25","type":"Alternate Question Text","description":"If patient has treated brain metastases does follow-up brain imaging after CNS-directed therapy show no evidence of progression by imaging for at least 4 weeks prior to the first dose of study treatment and any neurologic symptoms have returned to baseline, there is no evidence of new or enlarging brain metastases, and patient is not using steroids for at least 7 days prior to the first dose of study treatment?","url":null,"context":"Theradex"},{"name":"Theradex - 27","type":"Alternate Question Text","description":"If patient has previously treated brain metastases, are they stable with no evidence of new or enlarging brain metastases for at least 3 months and are not using steroids for at least 7 days prior to trial treatment?","url":null,"context":"Theradex"},{"name":"NRG CRF_Text_2","type":"Alternate Question Text","description":"If the patient has brain metastases that have been previously treated, does the follow up brain imaging after CNS-directed therapy show no evidence of progression?","url":null,"context":"NRG"},{"name":"Theradex - 28","type":"Alternate Question Text","description":"If patient has treated brain metastases does follow up brain imaging after central nervous system (CNS)-directed therapy show no evidence of progression and patient has been clinically stable for at least 1 month?","url":null,"context":"Theradex"},{"name":"Theradex - 29","type":"Alternate Question Text","description":"If patient has previously diagnosed brain metastases, have they completed treatment and have recovered from the acute effects of radiation therapy or surgery prior to study enrollment, and have discontinued corticosteroid treatment for these metastases for at least 2 weeks, and are neurologically stable?","url":null,"context":"Theradex"},{"name":"Theradex - 30","type":"Alternate Question Text","description":"If the patient has a history of treated CNS metastases are the following criteria met: disease outside the CNS is present and has recovered from acute toxicity associated with the treatment to less than or equal to CTCAE version 5.0 grade 1 or baseline (with the exception of alopecia), with no requirement for escalating doses of corticosteroids over the past 7 days?","url":null,"context":"Theradex"},{"name":"Theradex - 31","type":"Alternate Question Text","description":"If the patient has brain metastases, have they been treated?","url":null,"context":"Theradex"},{"name":"NRG CRF Text 1","type":"Alternate Question Text","description":"If the patients received prior therapies for brain and leptomeningeal metastasis or cord/cauda compression, have they been clinically stable for greater than or equal to 2 months prior to registration and have discontinued systemic therapy greater than 4 weeks prior to registration?","url":null,"context":"NRG"},{"name":"Theradex - 32","type":"Alternate Question Text","description":"If patient has prior brain metastasis, was patient treated with evidence of resolution or stable disease for 6 months?","url":null,"context":"Theradex"}],"origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"2CF20F00-C9CD-BD67-E050-BB89AD432467","latestVersionIndicator":"Yes","beginDate":"2016-02-29","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2016-02-29","modifiedBy":"SOKKERL","dateModified":"2023-03-30","changeDescription":"9881_Theradex_02.29.16_ghd","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}